Changchun High-Tech Industry (000661.SZ) subsidiary Kinse Pharmaceuticals has reached a cooperation agreement with Denmark's ALK on allergen-specific immunotherapy products.

Changchun High-Tech Industry (000661.SZ) announced that its controlling subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), has reached a cooperation agreement with Denmark's ALK-Abell A/S (hereinafter referred to as "ALK") on allergen-specific immunotherapy (AIT) products. They will jointly develop and commercialize ALK's house dust mite (HDM) allergen-specific immunotherapy products in China, and obtain the exclusive distribution rights for three products developed by ALK in mainland China. According to the agreement, Jinsai Pharmaceutical will have exclusive rights to distribute three products developed by ALK in mainland China, including subcutaneous house dust mite allergen preparations (ACARIZAX), mite allergen skin prick test kits (ALK PRICK), and dust mite allergen sublingual tablets (ACARIZAX). The cooperation rights will be valid until December 31, 2039. Jinsai Pharmaceutical will pay an initial payment of 32.7 million euros to obtain the commercial rights for the above-mentioned three products in mainland China.